ORTX - Orchard Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.35
-0.79 (-5.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.14
Open13.96
Bid13.20 x 2200
Ask13.27 x 800
Day's Range13.06 - 14.14
52 Week Range8.65 - 21.64
Volume195,858
Avg. Volume208,998
Market Cap1.147B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire14 days ago

    Orchard Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference on June 12, 2019

    BOSTON and LONDON, June 10, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire19 days ago

    Orchard Therapeutics Announced Pricing of Public Offering

    BOSTON and LONDON, June 05, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire21 days ago

    Orchard Therapeutics Launches Proposed Public Offering

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the launch of a proposed public offering of 9,000,000 American Depositary Shares (“ADSs”) representing 9,000,000 ordinary shares. Each of the ADSs are being offered by Orchard. Orchard expects to grant the underwriters a 30-day option to purchase up to 1,350,000 additional ADSs.

  • GlobeNewswire27 days ago

    Orchard Therapeutics Announces Expansion of Neurometabolic Disease Portfolio and Reports First Quarter 2019 Financial Results

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced financial results for the quarter ended March 31, 2019 and provided several program updates related to its neurometabolic disease portfolio. Orchard has brought forward the timeline for key clinical and regulatory milestones for two of its neurometabolic disease programs and, as announced in a separate release this morning, has secured an exclusive worldwide license for a clinical-stage ex vivo autologous hematopoietic stem cell (HSC) gene therapy program in Mucopolysaccharidosis Type I (MPS-I). “The progress we’ve made advancing ex vivo autologous hematopoietic stem cell-based gene therapies aimed at correcting neurometabolic diseases furthers our confidence in the potential of our technology to treat additional serious, often fatal, rare diseases that to date have been difficult or impossible to treat,” said Mark Rothera, president and chief executive officer of Orchard.

  • GlobeNewswire27 days ago

    Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele Announce Exclusive Worldwide License Agreement for the Treatment of MPS-I

    Orchard Therapeutics (ORTX), Fondazione Telethon and Ospedale San Raffaele today announced that Orchard has been granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the ex vivo autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of Mucopolysaccharidosis Type I (MPS-I) developed by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. The clinical-stage program is currently enrolling patients in an ongoing proof-of-concept study.

  • GlobeNewswirelast month

    Orchard Therapeutics to Webcast Conference Call of First Quarter 2019 Financial Results on May 28, 2019

    BOSTON and LONDON, May 22, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire2 months ago

    Orchard Therapeutics Announces Clinical Proof-of-Concept Data for Gene Therapy OTL-300 Demonstrating Efficacy in Transfusion-Dependent Beta-Thalassemia

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the presentation of the full clinical proof-of-concept data from its trial of ex vivo, autologous, hematopoietic stem cell (HSC) gene therapy, OTL-300, for the treatment of transfusion-dependent beta-thalassemia (TDT). The data will be featured today in an oral presentation at the 22nd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C.

  • GlobeNewswire2 months ago

    Orchard Therapeutics Strengthens Commercial Leadership Team with Appointment of Francis Pang as Vice President of Global Market Access

    BOSTON and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Francis Pang as vice president of global market access. Mr. Pang will be responsible for developing and executing on global pricing and market access strategies to ensure that Orchard’s ex vivo autologous hematopoietic stem cell (HSC) gene therapies, if approved, are reimbursed by healthcare systems worldwide.

  • GlobeNewswire2 months ago

    Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome

    BOSTON and LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the first patient with Wiskott-Aldrich Syndrome (WAS) has been dosed in a open label study designed to evaluate engraftment of the cryopreserved formulation of OTL-103, its ex vivo autologous hematopoietic stem cell (HSC) gene therapy. “We are excited to have reached this milestone with the infusion of cryopreserved gene-modified stem cells in a patient with Wiskott-Aldrich Syndrome, a life-threatening immune disorder for which there is no available therapy outside of allogeneic stem cell transplantation, which carries a significant risk of morbidity and mortality,” said Mark Rothera, president and chief executive officer of Orchard.

  • GlobeNewswire2 months ago

    Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the achievement of clinical proof-of-concept based on data from the trial of its ex vivo, autologous, hematopoietic stem cell (HSC) gene therapy, OTL-300, for the treatment of transfusion-dependent beta-thalassemia (TDT). The data will be published online today in an abstract via the American Society of Gene & Cell Therapy (ASGCT) website, and the full data set will be featured in an oral presentation at the 22nd ASGCT Annual Meeting to be held on April 29 – May 2, 2019 in Washington, D.C. Specifically, the presentation will report the updated safety and efficacy results of OTL-300 in nine transfusion-dependent severe phenotype TDT patients (six pediatric, three adult), including β0/β0 genotype, with minimum one year post-treatment follow up, as well as details on engraftment of gene-modified cells and vector integration site analyses.

  • GlobeNewswire3 months ago

    Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, presented the full registrational dataset from a 20 patient trial evaluating the efficacy and safety of OTL-200, an ex vivo autologous hematopoietic stem cell-based (HSC) gene therapy for the treatment of metachromatic leukodystrophy (MLD). The data, which included updated results on the two-year primary endpoints, in addition to new follow-up data at three years, were featured yesterday in an oral presentation at the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

  • GlobeNewswire3 months ago

    Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights

    Three Lead Programs for MLD, ADA-SCID and WAS on Track for Regulatory Filings Over the Next Three Years, with MLD and ADA-SCID Expected in 2020 Registrational Data Showing 100%.

  • GlobeNewswire3 months ago

    Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Ran Zheng to the newly created position of chief technical officer. Upon joining Orchard, Ms. Zheng will oversee multiple related functions, including process development, manufacturing, quality, facilities and engineering, supply chain, and CMC program management. Ms. Zheng, who brings more than 20 years of experience in technical operations, will report to Mark Rothera, president and chief executive officer of Orchard, and serve as a member of the executive leadership team.

  • GlobeNewswire3 months ago

    Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019

    BOSTON and LONDON, March 14, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire3 months ago

    Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that new clinical data from the registrational trial of OTL-200 in metachromatic leukodystrophy (MLD) will be featured in an oral presentation at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) to be held on March 24-27, 2019 in Frankfurt, Germany. The presentation will feature updated safety and efficacy results from patients with a minimum of three years of follow-up following treatment with gene therapy.

  • GlobeNewswire4 months ago

    Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019

    BOSTON and LONDON, March 04, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire4 months ago

    Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD

    BOSTON and LONDON, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, yesterday presented additional clinical proof-of-concept data evaluating OTL-102, an ex vivo, autologous, hematopoietic stem cell based gene therapy for the treatment of X-linked chronic granulomatous disease (X-CGD) during an oral presentation at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR in Houston, TX. The proof-of-concept data was first presented during the Presidential Symposium at the American Society of Hematology (ASH) Annual Meeting & Exposition in December 2018.

  • GlobeNewswire4 months ago

    Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID

    100% Overall Survival and 100% Event Free Survival in Patients Treated with OTL-101 Compared to 88% OS and 56% EvFS with Historical HSCT Overall at 24 months Biologics License.

  • GlobeNewswire5 months ago

    Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR

    BOSTON and LONDON, Feb. 06, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire5 months ago

    Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) has published encouraging results from a clinical trial of OTL-300, an autologous ex vivo lentiviral gene therapy program being studied in individuals with transfusion-dependent beta-thalassemia. “Orchard recognizes the pioneering work of researchers and clinicians from SR-Tiget that has led to this peer-reviewed publication of promising clinical data for the treatment of transfusion-dependent beta-thalassemia patients in Nature Medicine,” said Andrea Spezzi, M.D., chief medical officer of Orchard Therapeutics.

  • GlobeNewswire6 months ago

    Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy

    BOSTON and LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today summarized recent accomplishments and 2019 strategic priorities in conjunction with its attendance at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. Mark Rothera, president and chief executive officer, will present a business overview outlining the company’s progress as a global leader in gene therapy on Wednesday, January 9, 2019 at 3:00 p.m. PT that will be webcast at ir.orchard-tx.com. “2018 was a momentous year for Orchard, marked by the success of our acquisition and integration of GSK’s rare disease ex-vivo gene therapy portfolio, initial scaling of our manufacturing capabilities and completion of our initial public offering,” said Mr. Rothera.

  • GlobeNewswire6 months ago

    Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019

    BOSTON and LONDON, Jan. 02, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire6 months ago

    Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that it has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California. The new 150,000-square-foot facility significantly increases Orchard’s California footprint and adds to the Foster City and Menlo Park, California sites, which oversee the ongoing development and validation of the manufacture of Orchard’s ex vivo gene therapy product candidates.

  • GlobeNewswire7 months ago

    Orchard Therapeutics Appoints Industry Veteran Alicia Secor to its Board of Directors

    BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Alicia Secor to its board of directors. Ms. Secor brings more than 25 years of life sciences leadership and commercial product expertise with a particular focus in rare disease and other areas of unmet need, most recently serving as president and chief executive officer at Juniper Pharmaceuticals, Inc.